Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-20T03:16:05.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:45:43.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T19:43:31.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page now includes information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Previous revision dates have been removed.
    Difference
    2%
    Check dated 2025-05-29T15:04:35.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T23:41:50.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the removal of detailed eligibility criteria and study objectives for a clinical trial on pembrolizumab for head and neck squamous cell carcinoma, while retaining the study's title and collaborator information.
    Difference
    50%
    Check dated 2025-04-16T14:48:30.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.